Related Experiment Video

Updated: Jun 6, 2025

Rapid Synthesis and Screening of Chemically Activated Transcription Factors with GFP-based Reporters
09:22

Rapid Synthesis and Screening of Chemically Activated Transcription Factors with GFP-based Reporters

Published on: November 26, 2013

14.5K

Expression, molecular mechanisms and therapeutic potentials of ATF1 in cancers

Ziwen Lu1, Hangyu Dong2, Zhigang Tu1

  • 1School of Life Sciences, Jiangsu University, Zhenjiang, Jiangsu 212013, China.

Life Sciences
|November 23, 2024
PubMed

Insights

Activating transcription factor 1 (ATF1) is overexpressed in many cancers, driving tumor progression and resistance. Targeting ATF1 offers potential for novel cancer therapies and improved patient outcomes.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cancer Research

Background:

  • Activating transcription factor 1 (ATF1) is a key regulator in the ATF/CREB family.
  • Misregulation of ATF1 is implicated in the development and progression of various cancers.
  • ATF1 influences gene expression in response to extracellular signals, impacting cellular processes relevant to cancer.

Purpose of the Study:

  • To review the structural features of ATF1.
  • To examine the role of ATF1 in tumorigenesis and cancer progression.
  • To explore potential therapeutic strategies targeting ATF1 for cancer treatment.

Main Methods:

  • Literature review of data from multiple databases.
  • Analysis of ATF1's role in cancer hallmarks like proliferation, apoptosis, migration, and invasion.
  • Investigation of ATF1's interactions within cellular regulatory networks.

Main Results:

  • Consistent overexpression of ATF1 in diverse cancers, correlating with poor prognosis and aggressive phenotypes.
  • ATF1 influences critical cancer processes including cell proliferation, apoptosis, migration, invasion, and therapeutic resistance.
  • Preclinical models demonstrate efficacy of emerging ATF1-targeting strategies like antibodies, natural compounds, and small molecule inhibitors.

Conclusions:

  • ATF1 is a significant factor in cancer progression and therapeutic resistance.
  • Targeting ATF1 presents a promising avenue for developing novel cancer therapies.
  • Further research into ATF1's role in the tumor microenvironment and immune interactions may unlock new immunotherapeutic strategies.
Keywords:
ATF1Anti-cancer therapyCancerExpressionMolecular mechanism

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.5K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

759

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K